Leica Biosystems specializes in automated cancer diagnostics. Financial terms were not disclosed.
Devicor, which has about 400 employees worldwide, was created by private equity firm GTCR. In 2010, the company acquired the Mammotome breast-care business from Johnson & Johnson (NYSE:JNJ), which it eventually expanded with new product lines and markets. Devicor posts annual revenues of roughly $170 million, according to a press release.
"Leica Biosystems’ products and solutions address the key steps across the anatomic pathology workflow. The addition of Devicor’s market leading breast biopsy products, especially Mammotome, allows us to further integrate that workflow from the source, starting with the patient and the biopsy sample," CEO Dr. Matthias Weber said in prepared remarks. "This acquisition supports our mission of advancing cancer diagnostics to improve lives by adding products that will have direct benefits for the patients and the clinicians who care for them.”
In September, Danaher agreed to acquire dental-implant maker Nobel Biocare for approximately $2.14 billion.
Danaher said the Devicor business will operate under its own banner within Leica Biosystems, with CEO Tom Daulton continuing to lead the unit.